Aspira Women's Health’s Post

I challenge you to listen to the latest edition of OvaView with Victoria Haverbusch and not get excited about #OvaWatch.This one-of-a-kind proprietary blood test has demonstrated its accuracy in assessing the risk of malignancy in women with an adnexal mass, a breakthrough by any measure. For far too long, a lack of confidence in non-invasive methods of assessing ovarian cancer risk has led us to resort to surgical intervention even though the vast majority of the masses turn out to be benign. Aspira Women's Health is going to change that. The use of #OvaWatch initial clinical assessment and ongoing mass monitoring can reduce unnecessary surgery and surgical menopause while simultaneously improving a clinician's ability to identify those patients that require additional care and clinical intervention. #obgyn #innovation #dx #ovariancancer #gynecology #womenshealth #nursepractitioner

Introducing a new “OvaView” summary featuring Victoria Haverbusch, our expert in risk assessment. Explore the latest advancements in biomarker technology for assessing ovarian cancer risk in a concise video and gain valuable insights to enrich your clinical decision-making process.   #OvaView #AspiraWomensHealth #OvarianCancerAwareness #OvarianCancer #WomensHealth

Learn about the importance of biomarker testing in #cervical cancer and frontline treatment options for PD-L1+ persistent, recurrent, or metastatic disease in this CME activity. #RMEI #CME #MedEd https://ow.ly/weIc50Qusag

Learn about the importance of biomarker testing in #cervical cancer and frontline treatment options for PD-L1+ persistent, recurrent, or metastatic disease in this CME activity. #RMEI #CME #MedEd https://ow.ly/weIc50Qusag

Learn about the importance of biomarker testing in #cervical cancer and frontline treatment options for PD-L1+ persistent, recurrent, or metastatic disease in this CME activity. #RMEI #CME #MedEd https://ow.ly/weIc50Qusag

https://lnkd.in/dG5c7Msu Advancing Cancer Diagnostics: The Minimal Residual Disease Testing Market, valued at USD 1.60 billion in 2023, is set for substantial growth with a projected CAGR of 12.8% from 2024 to 2030, reaching nearly USD 3.72 billion. . Enhancing precision in cancer detection. 🩺🔬 #maximizemarketresearch #CancerDiagnostics #MinimalResidualDisease #PrecisionMedicine #MedicalTechnology #HealthcareInnovation

A systematic review (DOI: 10.3390/ijms25074005) assessed circulating tumor DNA (ctDNA) in 628 anal cancer patients, indicating its high potential as a predictive biomarker for disease management. With a sensitivity of 82-100%, ctDNA levels correlate with treatment response and recurrence risk, suggesting its value in clinical decisions. #CancerManagement #PrecisionMedicine #HealthcareInnovation

🩺🔬The FDA has approved a new blood test for colon cancer detection, a significant step forward in cancer screening. This approval follows a recommendation from an FDA advisory committee, highlighting the test's potential to encourage screening among those who avoid traditional methods like fecal tests or colonoscopies. While the blood test doesn't replace the need for a colonoscopy if cancer is detected, it offers a less invasive initial screening option. Medicare part B will cover the test at no additional cost, potentially increasing accessibility and early detection for many. This advancement underscores the critical role of new technologies in improving patient outcomes and preventive care. #HealthcareInnovation #CancerScreening #ColonCancer #FDANews #MedicalAdvancements #PatientCare #EarlyDetection #MedicareCoverage #HealthTech Read more: https://lnkd.in/e7myTYCC

Merus N.V.' Petosemtamab is emerging as a potential best-in-class option for first-line HNSCC treatment Despite existing standard therapies, HNSCC poses a significant threat with a poor prognosis. Petosemtamab, a human IgG1 bispecific antibody targeting EGFR and LGR5, exhibits ADCC-enhanced activity. Its combination with pembrolizumab is currently under investigation in a Phase II study expansion cohort for 1L HNSCC. Initial findings presented at ASCO reveal clinically meaningful activity and favorable safety, with an impressive overall response rate of 67%. Despite recent strides, HNSCC remains a deadly disease with limited treatment options. However, the synergistic approach of petosemtamab and pembrolizumab shows promise as a potential game-changer, poised to redefine treatment standards for untreated head and neck cancer patients. Benefit from Expert Insights and Extensive Analysis with DelveInsight Business Research LLP's American Society of Clinical Oncology (ASCO) 2024 Exclusive Coverage @ https://lnkd.in/g2i9yJ4D #asco24 #asco #asco2024 #ascoconference #Merus #Petosemtamab #HNSCC #FirstLineTreatment #EGFR #LGR5 #BispecificAntibody #ClinicalTrials #ASCO #Immunotherapy #CancerTreatment #ClinicalResearch #MedicalInnovation #CancerTherapy

📰 BREAKING NEWS: Promising new medication offers exciting advancements in slowing early-stage lung cancer development. Key Highlights: 1️⃣ According to company research, AstraZeneca's Tagrisso demonstrates a significant improvement in progression-free survival (PFS) as a maintenance treatment following chemoradiotherapy. 2️⃣ The study hints at a positive trend in overall survival (OS), with further data collection underway. 3️⃣ Should Tagrisso continue to prove effective, countless lives could be saved through critical early intervention. 💬 What are your thoughts on this new development in lung cancer treatment? Share below! 👉 And follow Body Vision Medical for the latest in medical innovation. #LungCancer #CancerTreatment #MedicalInnovation #Healthcare